Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
August 11, 2020 04:06 ET
|
Kymab Group Ltd
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON
June 24, 2020 05:29 ET
|
Kymab Group Ltd
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company...
Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents
June 03, 2020 07:00 ET
|
Kymab Group Ltd
Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for invalidation of Kymab’s US patents USPTO upholds a fifth Kymab patent covering Human Antibodies and...
Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron
April 14, 2020 07:00 ET
|
Kymab Group Ltd
Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron USPTO upholds 4 Kymab patents covering Human Antibodies and Platforms Cambridge, UK:...
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
September 27, 2019 02:00 ET
|
Kymab Group Ltd
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor...
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting
June 01, 2019 07:00 ET
|
Kymab Group Ltd
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson...
Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer
April 08, 2019 07:00 ET
|
Kymab Group Ltd
Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics,...
Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases
July 30, 2018 04:00 ET
|
Kymab Group Ltd
Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases Top-line Phase I data demonstrated favorable safety, pharmacokinetics and...